TY  - GEN
AU  - Mahadevan,D
AU  - Chiorean,E G
AU  - Harris,W B
AU  - Von Hoff,D D
AU  - Stejskal-Barnett,A
AU  - Qi,W
AU  - Anthony,S P
AU  - Younger,A E
AU  - Rensvold,D M
AU  - Cordova,F
AU  - Shelton,C F
AU  - Becker,M D
AU  - Garlich,J R
AU  - Durden,D L
AU  - Ramanathan,R K
TI  - Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
SN  - 1879-0852
PY  - 2013///0214
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Chromones
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Gastrointestinal Diseases
KW  - chemically induced
KW  - Hematologic Diseases
KW  - Humans
KW  - Hypokalemia
KW  - Infusions, Intravenous
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Multiprotein Complexes
KW  - Neoplasm Proteins
KW  - antagonists & inhibitors
KW  - Neoplasms
KW  - Oligopeptides
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Prodrugs
KW  - Protein Kinase Inhibitors
KW  - Proteins
KW  - Salvage Therapy
KW  - TOR Serine-Threonine Kinases
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.ejca.2012.06.027
ER  -